The pharmaceutical industry stands at a critical juncture, balancing the rapid acceleration of artificial intelligence, the maturation of organ-on-a-chip technologies, and the ever-tightening grip of global regulatory scrutiny. As the landscape of drug discovery and development becomes increasingly complex, the need for a collaborative, science-first forum has never been more urgent.
From October 25 to 28, 2026, the Ernest N. Morial Convention Center in New Orleans will serve as the epicenter for this global exchange. AAPS PharmSci 360, the flagship event of the American Association of Pharmaceutical Scientists (AAPS), returns to provide a comprehensive look at the entire pharmaceutical product lifecycle. Bringing together thousands of researchers, executives, and innovators from across the globe, the conference promises to dismantle the silos that often hinder drug development, offering a high-level autopsy of current industry challenges and a glimpse into the next decade of therapeutic innovation.
The Core Mission: A Holistic View of the Product Lifecycle
The strength of AAPS PharmSci 360 lies in its breadth. Unlike niche symposia, this event traverses the entire spectrum of pharmaceutical development, from the initial bench-side discovery to the complex regulatory and clinical realities of bringing a drug to market. The 2026 program is curated to address the "science-first" ethos, ensuring that every session—whether focused on basic research or executive strategy—is grounded in empirical rigor.
This year’s event features an unprecedented diversity of organizations, ranging from emerging biotech startups to industry titans such as AstraZeneca, Merck, Eli Lilly, and the Mayo Clinic. By fostering dialogue between these diverse entities, the conference aims to streamline the path from innovation to patient impact.
Chronological Breakdown: A Roadmap of the 2026 Program
The four-day event is meticulously structured to guide attendees through distinct thematic tracks, ensuring that every day offers tangible value for both academic researchers and industrial practitioners.
Monday, October 26: The Intersection of Strategy and Biology
The week kicks off with a heavy emphasis on the operational and biological underpinnings of development. A standout session, "What Actually Drives Development Speed? An Executive-Level Autopsy of Drug Development Delays," will feature a powerhouse panel including Dr. Leigh Verbois, CEO of Rx-360, and Dr. Teresa R. Henry of Blue Oaks Biotech. This session promises to strip away the industry-standard platitudes to identify the true, granular causes of clinical trial bottlenecks.
Simultaneously, the technical sessions will dive deep into regulatory and cellular biology:
- Regulatory Precision: Dr. Nagendra Chemuturi (Eli Lilly) will lead a session on designing regulatory-ready biodistribution strategies under ICH S12 guidelines.
- Cellular Models: Dr. Kim L.R. Brouwer (UNC Eshelman School of Pharmacy) will discuss the cutting-edge of hepatic systems, including sandwich-cultured hepatocytes and liver-on-a-chip technology.
- Immunogenicity: Dr. Benjamin Gabriel (EpiVax) will address the evolving landscape of new approach methodologies (NAMs) for immunogenicity risk assessment.
Tuesday, October 27: The Era of Advanced Modalities
Tuesday shifts the focus toward the "next generation" of drug delivery and toxicity modeling. As personalized medicine moves from theory to practice, the technologies showcased on this day will be pivotal.
- Nanomedicine: Dr. Annette Bak (AstraZeneca) will explore the translation of nanomedicine from initial design to successful therapeutic outcomes.
- Clinical Consequences: A highly anticipated session by Dr. Jessica Atieh (Mayo Clinic) will examine the clinical implications of GLP-1-induced gastric emptying, a topic of massive current interest given the global boom in weight-loss and metabolic therapies.
- Microphysiological Systems: The afternoon will focus on organ-on-a-chip advancements, with presentations from Jing Bai (Xellar Biosystems) and Christine M. Hamadani (Merck) highlighting human lymphoid and liver-on-a-chip models for DILI (drug-induced liver injury) and vaccine evaluation.
Wednesday, October 28: Modeling, Policy, and the Path Forward
The final day focuses on the future-proofing of the pharmaceutical pipeline.
- Dose Selection: Dr. Ran Li (Genentech) will tackle the complex math behind dose selection for multispecific biologics.
- Regulatory Harmonization: A "Hot Topic" session will address the critical question: "Are regulators on the same page for pediatric drug data?" This session features Dr. John J. Alexander from the U.S. FDA and Dr. Alysha Croker from Health Canada, providing a rare opportunity for attendees to hear directly from the entities that hold the keys to market approval.
Supporting Data: Why NAMs and Integrity Matter
Two of the most significant additions to the 2026 program are the "Innovator-Curated" tracks. These tracks are not merely content-driven; they are mission-driven.
The first track, inaugurated by Brian Nosek on October 26, focuses on Research Integrity. As the industry faces increasing scrutiny regarding reproducibility and data transparency, this track offers a vital forum for discussing how the pharmaceutical sector can maintain the highest standards of scientific honesty.
The second track, led by Dr. Thomas Hartung (Johns Hopkins University) on October 28, centers on New Approach Methodologies (NAMs). The shift away from traditional animal models toward human-centric, silicon-based, or microphysiological testing is one of the most consequential shifts in the history of pharmacology. By bringing together experts from Tulane University, 28Bio, and VeriSim Life, this track provides a roadmap for companies looking to integrate these technologies into their workflows to reduce costs, increase speed, and improve human-relevance in toxicology data.
Official Perspectives: Shaping the Industry Narrative
The event is framed by two major plenary addresses that set the tone for the week. On Sunday, October 25, Dr. Julie Gerberding, President and CEO of the Foundation for the National Institutes of Health (FNIH), will open the proceedings with a focus on public health. Her perspective on the symbiotic relationship between pharmaceutical innovation and societal health needs will provide a high-level context for the technical sessions that follow.
Closing the event on Wednesday, October 28, Dr. David Berry (Averin Capital) will offer an investor’s perspective on how technology is fundamentally altering the pharmaceutical market. This "look ahead" is intended to help scientists understand not just the how of their work, but the market viability of their innovations.
Implications for the Industry: The USP Partnership and Career Growth
Perhaps the most practical, hands-on development at this year’s PharmSci 360 is the new partnership with the United States Pharmacopeia (USP). By hosting dedicated sessions inside the exhibit hall, the USP is making complex topics—such as excipient quality, inhalation standards, and the nuances of complex generics—accessible to every attendee. This direct line of communication between the USP and the bench scientist is expected to demystify the regulatory standards that often prove to be the most frustrating hurdles in product development.
Furthermore, the "Careers 360" resources acknowledge that the industry is changing not just in its science, but in its professional requirements. With sessions dedicated to AI skill-building, startup funding strategies, and intellectual property (IP) navigation, the conference is positioning itself as a career catalyst. In an environment where AI is rapidly augmenting, and in some cases replacing, traditional medicinal chemistry and data analysis roles, the focus on "re-skilling" is a timely and necessary inclusion.
Conclusion: A Call to Action
AAPS PharmSci 360 in New Orleans is more than a gathering; it is an infrastructure for progress. By uniting the minds behind the most complex biologics, the experts navigating the labyrinth of global regulations, and the visionaries building the next generation of organ-on-a-chip models, AAPS is providing a vital service to the pharmaceutical ecosystem.
As the industry faces the dual pressure of increasing therapeutic efficacy and decreasing development time, the answers will not be found in isolation. They will be found in the exchange of ideas between the bench and the boardroom, the academic lab and the regulatory agency. For scientists and leaders looking to sharpen their edge, engage with the leading edge of technology, and build a network that spans the globe, the October 25-28 event in New Orleans represents the premier opportunity of the year.
Registration is currently open for those looking to secure their place at this definitive industry gathering.
About the Author
